Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16736837 | 0.86 | CA1 (0.37) | GSK3AGSK3BAAK1ALPLCA1 | |
| SCHEMBL17501149 | 0.82 | LPL (0.37) | GSK3AGSK3BAAK1ALPLCA1 | |
| SCHEMBL15056826 | 0.80 | ALPL (0.37) | GSK3AGSK3BAAK1ALPLCA1 | |
| SCHEMBL15056858 | 0.79 | ALPL (0.36) | GSK3AGSK3BAAK1ALPLCA1 | |
| SCHEMBL15056872 | 0.78 | AAK1 (0.47) | GSK3AGSK3BAAK1ALPLCA1 | |
| SCHEMBL15057096 | 0.78 | PDGFRB (0.36) | GSK3AGSK3BAAK1ALPLCA1 | |
| SCHEMBL15079362 | 0.77 | CA1 (0.38) | GSK3AGSK3BAAK1ALPLCA1 | |
| SCHEMBL24169056 | 0.76 | CA1 (0.42) | CA1CA2CA9CA12CA3 | |
| SCHEMBL15056968 | 0.75 | AAK1 (0.44) | GSK3AGSK3BAAK1ALPLCA1 | |
| SCHEMBL19759441 | 0.73 | GSK3A (0.42) | GSK3AGSK3BAAK1DGAT1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150148377-A1 | Quinoline Derivatives | NOVARTIS AG (CH) | 2015-05-28 | — | — | US | disclosed |
| US-20150148377-A1 | Quinoline Derivatives | NOVARTIS AG (CH) | 2015-05-28 | — | — | US | disclosed |
| US-20150148377-A1 | Quinoline Derivatives | NOVARTIS AG (CH) | 2015-05-28 | — | — | US | disclosed |
| WO-2013093850-A1 | QUINOLINE DERIVATIVES | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148377-A1 | Quinoline Derivatives | RECQL, NQO2, PIK3R3 | GSK3A 266/4885GSK3B 235/4885AAK1 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.